GLP-1

RecruitingPhase EARLY_1

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

The Role of Glucagon Like Peptide-1 in Glucose Metabolism and Weight Loss Following Gastric Bypass Surgery

Lead sponsor

The University of Texas Health Science Center at San Antonio

Asset

Avexitide

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight

Eligibility highlights

•Healthy volunteers

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01803451

Org study IDHSC20180070H

Secondary IDDK083554NIDDK

Timeline

Milestones

Study first posted2013-03-04estimated

Last update posted2025-09-09actual

Study start2005-11 (month precision)

Primary completion2026-08estimated (month precision)

Study completion2027-08estimated (month precision)

Assets

Investigational agents

Avexitide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•age 18-65

•healthy control without diabetes or active organ disease

•Individuals with bariatric surgery

•recurrent hypoglycemia post gastric bypass

Exclusion criteria

•pregnancy

•significant anemia

•diabetes currently unless pre-op for bariatric surgery procedure

•GI obstruction

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.